Publisher
Springer Berlin Heidelberg
Reference95 articles.
1. Practice guideline report;Breast Cancer Disease Site Group,2003
2. Esteva FJ, Valero V, Booser D (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER2 overexpressing metastatic breast cancer. J Clin Oncol 20: 1800–1808
3. Guidelines for diagnostic and therapy of breast carcinomas (2005). Version 2005 (2005) http://www.cancercare.on.ca/pdf/pebc1-18f.pdf
4. Ahmann DL, Schaid DJ, Bisel HF, Hahn RG, Edmonson JH, Ingle JN (1998) The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug. J Clin Oncol 5: 1928–1932
5. Albain KS, Nag S, Calderillo-Ruiz G et al. (2004) Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol 22: 510 (Abstract)